More info about Onno van de Stolpe

Company
Galapagos B.V.

Function
CEO

Onno van de Stolpe founded our company in 1999 and has served as our Chief Executive Officer and a member of our board of directors from 1999 to the present. From 1998 to 1999, he was the Managing Director of Genomics at IntroGene BV (later Crucell NV, which was acquired by Johnson & Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe BV. He established the European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager of Business Development at MOGEN International NV in Leiden. He received an MSc degree from Wageningen University. Mr. van de Stolpe has previously served as a member of the board of directors of DCPrime BV and as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies.

More info about Marc Martens

Company
Bird & Bird

Function
Head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels

As co-head of our International Life Sciences & Healthcare group and head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels, I provide cutting edge strategic and regulatory advice to our life sciences clients and represent them in litigation.

More info about Aliki Nichogiannopoulou

Company
European Patent Office

Function
Director

More info about Ton van der Hoven

Company
SurgVision BV

Function
CEO

More info about Bruno Vandermeulen

Company
Independent IP practitioner

Function
IP Lawyer - Member of the Brussels Bar

Bruno is an international IP litigation and transactional specialist with 30 years of experience in major law firms. He founded and managed the Belgian IP practice of the international law firm Bird & Bird during twenty years, where he litigated and negotiated dozens of cross border patent and technology transfer disputes in the sector of Life Sciences, Chemical and Electronics. He is currently an independent IP practitioner working in Brussels.

More info about Maurits Westerik

Company
Coupry

Function
IE/IT lawyer

More info about Bart Swinkels

Company
NLO

Function
Partner

Bart Swinkels has 24 years of experience in life science patenting. As a Dutch and European patent attorney and partner at NLO (European Patent and Trademark Attorneys) he specializes in drafting and prosecuting complex patent applications in all areas of biotechnology, including molecular biology, genomics, immunology, gene therapy, antibodies, drug targeting, metabolic engineering, bioinformatics, microbiology, and classical and molecular plant genetics. Bart advises biotech firms on their IP strategy and is also frequently engaged in biotech patent litigation. Bart holds a MSc in (bio)chemistry (cum laude, 1985) and a PhD in molecular biology under Prof. Piet Borst, from the University of Amsterdam (1989). Prior to joining NLO in 2000 he headed the IP department of the Pharming Group in Leiden (Netherlands) and he has worked as a European patent attorney with DSM/Gist-brocades in Delft (Netherlands). Previously he also worked as a molecular biologist in both academic and industrial research settings at Gist-brocades, the University of California at San Diego and the Netherlands Cancer Institute. In addition, Bart is the Dutch representative in the Biotech Committee of the Institute of Professional Representatives before the European Patent Office (EPI).

More info about Karin Verzijden

Company
Axon Lawyers

Function
Food and Pharma Lawyer

Karin is a food and pharma lawyer and assists food business operators, biotech companies, and  manufacturers of pharmaceuticals with bringing innovative products to the market. In particular, Karin helps concluding various commercial and R&D driven (licensing) transactions. She thereby applies her specific legal and business expertise on food and pharma, including clinical trials, medical foods, Novel Foods, and food supplements. In this framework, Karin also advises on the use of nutrition and health claims in relation to food products and how to avoid using medical claims. She represents clients both in civil proceedings and before the Advertising Code Committee – a self-regulatory body competent to hear claims on food and consumer products. Karin reports current food law developments on the blog www.foodhealthlegal.com.

More info about Kees Recourt

Company
Mibiton Foundation

Function
Investment Manager

Kees joined the Mibiton Foundation in 2004, a specialized fund which invested about €30 million in the innovative Dutch Life Sciences infrastructure. He holds a BSc in Electrical Engineering, a PhD in Molecular Biology (Leiden University, 1991) and learned the investment principles at the Private Equity training of the NVP (Amsterdam, 2001). During his research career in Wageningen, the Netherlands, he specialized in the molecular quality of food products and worked for various food companies. In 1999, he shifted towards the commercialization of technology at Licentec, a former company of ABN-AMRO and NPM Capital (Bilthoven). During this period, he was CEO of an Academic Medical Center start-up company, developing a bio-artificial liver device. Since 2005, Kees represents Mibiton as a board member of BioConnection BV, a commercial pharmaceutical GMP facility at the Pivot Park (Oss, the Netherlands). In addition, he is chairman of the ‘Take-off’ Life Sciences PreSeed fund, an initiative of the Netherlands Organisation for Scientific Research (NWO) and the Dutch Ministry of Economic Affairs. Kees is part time employed at the PaulJanssen Futurelab Leiden and is currently developing the Intellectual Property and Financial modules.